Plain-English translation of NCT06780085 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Carcinoma, Non-Small-Cell Lung research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing two newer investigational medications— and —compared to a standard chemotherapy drug (docetaxel) for people with advanced lung cancer that has progressed despite prior treatment. The study aims to see whether these new treatments might work better or be easier to tolerate than current standard options. You would receive your assigned medication as an intravenous infusion every 3 weeks.
Many people with advanced lung cancer eventually stop responding to standard immunotherapy and chemotherapy combinations. This trial exists to find new treatment options for these patients who have limited choices and need additional help controlling their disease.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic every 3 weeks to receive your assigned medication as an intravenous infusion. The study continues until your cancer progresses, you experience unmanageable side effects, or your doctor determines you should stop. Throughout the trial, you'll have regular blood tests, imaging scans, and checkups to monitor how well the treatment is working and watch for any side effects. The study team will also collect tumor tissue samples before and during treatment to better understand how the medication affects your cancer.
AI-generated summary from trial data · Jul 14, 2026 · Not medical advice
United States
Chile